- $6.97bn
- $7.44bn
- $999.59m
- 99
- 17
- 93
- 79
Annual income statement for HealthEquity, fiscal year end - January 31st, USD millions except per share, conversion factor applied.
2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | 2024 January 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 532 | 734 | 757 | 862 | 1,000 |
| Cost of Revenue | |||||
| Gross Profit | 326 | 415 | 424 | 490 | 623 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 496 | 701 | 796 | 853 | 883 |
| Operating Profit | 36.2 | 32.9 | -39.1 | 9 | 116 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 43.2 | 4.14 | -66.7 | -38.1 | 75 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 39.7 | 8.83 | -44.3 | -26.1 | 55.7 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 39.7 | 8.83 | -44.3 | -26.1 | 55.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 39.7 | 8.83 | -44.3 | -26.1 | 55.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.56 | 0.723 | 0.09 | -0.089 | 0.74 |